APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-obesity Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-obesity Medicine Market Outlook and Growth Opportunities 2026

31 December 2025194 pages

Choose your research edition.

Industry ResearchAnti-obesity Medicine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-obesity Medicine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Anti-obesity Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-obesity Medicine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-obesity Medicine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Anti-obesity Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-obesity Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-obesity Medicine market include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anti-obesity Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-obesity Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-obesity Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-obesity Medicine market.

Anti-obesity Medicine Segment by Company

Eisai

Novo Nordisk

Merck

Roche

Pfizer

GlaxoSmithKline

Vivus

Orexigen Therapeutics

Boehringer Ingelheim

Arena Pharmaceuticals

Amylin Pharmaceuticals

Alizyme

Anti-obesity Medicine Segment by Type

Prescription Drugs

OTC Drugs

Anti-obesity Medicine Segment by Application

Men

Women

Anti-obesity Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anti-obesity Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-obesity Medicine key companies, revenue, market share, and recent developments.

3. To split the Anti-obesity Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-obesity Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-obesity Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-obesity Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-obesity Medicine industry.

Chapter 3: Detailed analysis of Anti-obesity Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-obesity Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-obesity Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-obesity Medicine Industry Trends Table 2. Anti-obesity Medicine Industry Drivers Table 3. Anti-obesity Medicine Industry Opportunities and Challenges Table 4. Anti-obesity Medicine Industry Restraints Table 5. Global Anti-obesity Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-obesity Medicine Revenue Share by Company (2021-2026) Table 7. Global Anti-obesity Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-obesity Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Anti-obesity Medicine Company, Product Type & Application Table 10. Global Anti-obesity Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-obesity Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Prescription Drugs Table 15. Significant Companies of OTC Drugs Table 16. Global Anti-obesity Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Anti-obesity Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Anti-obesity Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Anti-obesity Medicine Sales Value Share by Type (2021-2026) Table 20. Global Anti-obesity Medicine Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Men Table 22. Significant Companies of Women Table 23. Global Anti-obesity Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Anti-obesity Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Anti-obesity Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Anti-obesity Medicine Sales Value Share by Application (2021-2026) Table 27. Global Anti-obesity Medicine Sales Value Share by Application (2027-2032) Table 28. Global Anti-obesity Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anti-obesity Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Anti-obesity Medicine Sales Value Share by Region (2021-2026) Table 31. Global Anti-obesity Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Anti-obesity Medicine Sales Value Share by Region (2027-2032) Table 33. Global Anti-obesity Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-obesity Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Anti-obesity Medicine Sales Value Market Share by Country (2021-2026) Table 36. Global Anti-obesity Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Anti-obesity Medicine Sales Value Market Share by Country (2027-2032) Table 38. Eisai Company Information Table 39. Eisai Business Overview Table 40. Eisai Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Eisai Anti-obesity Medicine Product Portfolio Table 42. Eisai Recent Development Table 43. Novo Nordisk Company Information Table 44. Novo Nordisk Business Overview Table 45. Novo Nordisk Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Novo Nordisk Anti-obesity Medicine Product Portfolio Table 47. Novo Nordisk Recent Development Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Merck Anti-obesity Medicine Product Portfolio Table 52. Merck Recent Development Table 53. Roche Company Information Table 54. Roche Business Overview Table 55. Roche Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Roche Anti-obesity Medicine Product Portfolio Table 57. Roche Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Pfizer Anti-obesity Medicine Product Portfolio Table 62. Pfizer Recent Development Table 63. GlaxoSmithKline Company Information Table 64. GlaxoSmithKline Business Overview Table 65. GlaxoSmithKline Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. GlaxoSmithKline Anti-obesity Medicine Product Portfolio Table 67. GlaxoSmithKline Recent Development Table 68. Vivus Company Information Table 69. Vivus Business Overview Table 70. Vivus Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Vivus Anti-obesity Medicine Product Portfolio Table 72. Vivus Recent Development Table 73. Orexigen Therapeutics Company Information Table 74. Orexigen Therapeutics Business Overview Table 75. Orexigen Therapeutics Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Orexigen Therapeutics Anti-obesity Medicine Product Portfolio Table 77. Orexigen Therapeutics Recent Development Table 78. Boehringer Ingelheim Company Information Table 79. Boehringer Ingelheim Business Overview Table 80. Boehringer Ingelheim Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Boehringer Ingelheim Anti-obesity Medicine Product Portfolio Table 82. Boehringer Ingelheim Recent Development Table 83. Arena Pharmaceuticals Company Information Table 84. Arena Pharmaceuticals Business Overview Table 85. Arena Pharmaceuticals Anti-obesity Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio Table 87. Arena Pharmaceuticals Recent Development Table 88. Amylin Pharmaceuticals Company Information Table 89. Amylin Pharmaceuticals Business Overview Table 90. Amylin Pharmaceuticals Anti-obesity Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio Table 92. Amylin Pharmaceuticals Recent Development Table 93. Alizyme Company Information Table 94. Alizyme Business Overview Table 95. Alizyme Anti-obesity Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Alizyme Anti-obesity Medicine Product Portfolio Table 97. Alizyme Recent Development Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Anti-obesity Medicine Product Image Figure 2. Global Anti-obesity Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-obesity Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-obesity Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Prescription Drugs Image Figure 8. OTC Drugs Image Figure 9. Global Anti-obesity Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Anti-obesity Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Anti-obesity Medicine Sales Value Share by Type (2021-2032) Figure 12. Men Image Figure 13. Women Image Figure 14. Global Anti-obesity Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-obesity Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-obesity Medicine Sales Value Share by Application (2021-2032) Figure 17. Global Anti-obesity Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Anti-obesity Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Anti-obesity Medicine Sales Value (2021-2032) & (US$ Million) Figure 20. North America Anti-obesity Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Anti-obesity Medicine Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Anti-obesity Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Anti-obesity Medicine Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Anti-obesity Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Anti-obesity Medicine Sales Value (2021-2032) & (US$ Million) Figure 26. South America Anti-obesity Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Anti-obesity Medicine Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Anti-obesity Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Anti-obesity Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • OTC Drugs
Applications
  • Men
  • Women
Companies covered
  • Eisai
  • Novo Nordisk
  • Merck
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Vivus
  • Orexigen Therapeutics
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Amylin Pharmaceuticals
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-obesity Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-obesity Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-obesity Medicine Market Dynamics
  1. 2.1 Anti-obesity Medicine Industry Trends
  2. 2.2 Anti-obesity Medicine Industry Drivers
  3. 2.3 Anti-obesity Medicine Industry Opportunities and Challenges
  4. 2.4 Anti-obesity Medicine Industry Restraints
3 Anti-obesity Medicine Market by Company
  1. 3.1 Global Anti-obesity Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Anti-obesity Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Anti-obesity Medicine Company Ranking (2024-2026)
  4. 3.4 Global Anti-obesity Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-obesity Medicine Company Product Type and Application
  6. 3.6 Global Anti-obesity Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-obesity Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-obesity Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-obesity Medicine Market by Type
  1. 4.1 Anti-obesity Medicine Type Introduction
  2. 4.1.1 Prescription Drugs
  3. 4.1.2 OTC Drugs
  4. 4.2 Global Anti-obesity Medicine Sales Value by Type
  5. 4.2.1 Global Anti-obesity Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-obesity Medicine Sales Value by Type (2021-2032)
  7. 4.2.3 Global Anti-obesity Medicine Sales Value Share by Type (2021-2032)
5 Anti-obesity Medicine Market by Application
  1. 5.1 Anti-obesity Medicine Application Introduction
  2. 5.1.1 Men
  3. 5.1.2 Women
  4. 5.2 Global Anti-obesity Medicine Sales Value by Application
  5. 5.2.1 Global Anti-obesity Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anti-obesity Medicine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Anti-obesity Medicine Sales Value Share by Application (2021-2032)
6 Anti-obesity Medicine Regional Value Analysis
  1. 6.1 Global Anti-obesity Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-obesity Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-obesity Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-obesity Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-obesity Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Anti-obesity Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-obesity Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-obesity Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-obesity Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-obesity Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-obesity Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Anti-obesity Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-obesity Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-obesity Medicine Sales Value Share by Country, 2025 VS 2032
7 Anti-obesity Medicine Country-level Value Analysis
  1. 7.1 Global Anti-obesity Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-obesity Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-obesity Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-obesity Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-obesity Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-obesity Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-obesity Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Anti-obesity Medicine Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Anti-obesity Medicine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Anti-obesity Medicine Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Anti-obesity Medicine Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Vivus
  38. 8.7.1 Vivus Company Information
  39. 8.7.2 Vivus Business Overview
  40. 8.7.3 Vivus Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vivus Anti-obesity Medicine Product Portfolio
  42. 8.7.5 Vivus Recent Developments
  43. 8.8 Orexigen Therapeutics
  44. 8.8.1 Orexigen Therapeutics Company Information
  45. 8.8.2 Orexigen Therapeutics Business Overview
  46. 8.8.3 Orexigen Therapeutics Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
  48. 8.8.5 Orexigen Therapeutics Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
  55. 8.10 Arena Pharmaceuticals
  56. 8.10.1 Arena Pharmaceuticals Company Information
  57. 8.10.2 Arena Pharmaceuticals Business Overview
  58. 8.10.3 Arena Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
  60. 8.10.5 Arena Pharmaceuticals Recent Developments
  61. 8.11 Amylin Pharmaceuticals
  62. 8.11.1 Amylin Pharmaceuticals Company Information
  63. 8.11.2 Amylin Pharmaceuticals Business Overview
  64. 8.11.3 Amylin Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
  66. 8.11.5 Amylin Pharmaceuticals Recent Developments
  67. 8.12 Alizyme
  68. 8.12.1 Alizyme Company Information
  69. 8.12.2 Alizyme Business Overview
  70. 8.12.3 Alizyme Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Alizyme Anti-obesity Medicine Product Portfolio
  72. 8.12.5 Alizyme Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst